DERM vs. XERS, MGNX, EPIX, RVNC, INZY, CRMD, AQST, ATAI, ENTA, and XBIT
Should you be buying Journey Medical stock or one of its competitors? The main competitors of Journey Medical include Xeris Biopharma (XERS), MacroGenics (MGNX), ESSA Pharma (EPIX), Revance Therapeutics (RVNC), Inozyme Pharma (INZY), CorMedix (CRMD), Aquestive Therapeutics (AQST), Atai Life Sciences (ATAI), Enanta Pharmaceuticals (ENTA), and XBiotech (XBIT). These companies are all part of the "pharmaceutical preparations" industry.
Xeris Biopharma (NASDAQ:XERS) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.
Xeris Biopharma currently has a consensus target price of $4.63, indicating a potential upside of 107.40%. Journey Medical has a consensus target price of $8.50, indicating a potential upside of 115.19%. Given Xeris Biopharma's higher possible upside, analysts plainly believe Journey Medical is more favorable than Xeris Biopharma.
Xeris Biopharma received 139 more outperform votes than Journey Medical when rated by MarketBeat users. However, 100.00% of users gave Journey Medical an outperform vote while only 69.65% of users gave Xeris Biopharma an outperform vote.
In the previous week, Journey Medical had 5 more articles in the media than Xeris Biopharma. MarketBeat recorded 8 mentions for Journey Medical and 3 mentions for Xeris Biopharma. Journey Medical's average media sentiment score of 1.87 beat Xeris Biopharma's score of 0.44 indicating that Xeris Biopharma is being referred to more favorably in the media.
Xeris Biopharma has a beta of 2.37, suggesting that its share price is 137% more volatile than the S&P 500. Comparatively, Journey Medical has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500.
Journey Medical has a net margin of -5.20% compared to Journey Medical's net margin of -37.58%. Xeris Biopharma's return on equity of -32.83% beat Journey Medical's return on equity.
Journey Medical has lower revenue, but higher earnings than Xeris Biopharma. Journey Medical is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.
42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 4.6% of Xeris Biopharma shares are held by company insiders. Comparatively, 19.4% of Journey Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Journey Medical beats Xeris Biopharma on 9 of the 17 factors compared between the two stocks.
Get Journey Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DERM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Journey Medical Competitors List
Related Companies and Tools
